Sareum
Sareum is a drug discovery and development company, headquartered in Cambridge UK, that produces targeted small molecule therapeutics, focusing on cancer and autoimmune disease. Sareum aims to successfully deliver drug candidates for licensing to pharmaceutical and biotechnology companies at the pre-clinical or early clinical trials stage.
Sareum operates an outsourced research model, working with collaborators (SRI International, the CRT Pioneer Fund and Hebei Medical University Biomedical Engineering Center) and a world-wide network of research providers. Its research pipeline includes two programmes undergoing pre-clinical IND-enabling studies.
Contact Sareum via their website
News archive
01/07/2021 Sareum announces encouraging top-line results from Covid-19 project...more
01/06/2021 Sareum announces £900,000 raised through subscription...more
23/04/2021 Sareum plc announces its half-year results and operational highlights...more
25/03/2021 Sareum Notes SRA737 Combination Data to be Presented at the AACR Annual Meeting ...more
16/02/2021 Sareum Notes New UK Government Covid-19 Initiative...more
07/01/2021 US Patent Formally Granted for Sareum‘s SDC-1802 TYK2/JAK1 Inhibitor...more
14/12/2020 Sareum:Nature Article Highlights Role of TYK2 in Covid-19 ...more
03/12/2020 Sareum Awarded Grant Funding for Covid-19 therapy research...more
12/11/2020 Sareum Issues Update on SRA737 Licensing Agreement...more
27/10/2020 Sareum Notification of Grant Award for Covid-19 Research...more
08/10/2020 US Patent Allowance for Sareum's SDC-1802 TYK2/JAK1 Inhibitor...more
24/07/2020 Encouraging Preclinical Results Generated with Sareum‘s TYK2/JAK1 Inhibitors...more
02/06/2020 Sareum announces successful £1m fundraising...more
27/05/2020 Sareum to Present at BIO Bigital 2020...more
28/04/2020 Sareum presents update on 2 proprietary TYK2/JAK1 kinase inhibitor programmes...more
26/03/2020 Sareum Reports Global Licensing of FLT3+Auroa Programme...more
24/03/2020 Sareum Reports New SRA737 Combinations in Cancer...more
30/10/2019 Sareum presents data highlighting SDC-1802 anti-tumour activity...more
27/09/2019 Sareum TYK2/JAK1 Inhibitor SDC-1802 Demonstrates Anti-tumour Activity...more
28/06/2019 Sareum Raises Additional Funds through Placing and Offer...more
27/06/2019 Sareum Notes Sierra Seeks Strategic Options for SRA737...more
16/05/2019 Sareum reports ASCO Abstracts for SRA737 Published...more
08/05/2019 Sareum notes Sierra Oncology Q1 2019 Results...more
23/04/2019 Sareum Announces SRA737 Phase I/IIa data to be presented at ASCO...more
02/04/2019 Sareum's Preclinical Data for SRA737 Presented at AACR 2019...more
04/03/2019 Sareum announces its half-yearly results...more
28/02/2019 Sareum reports Sierra Oncology SRA737 data to be presented at AACR...more
23/01/2019 Sareum reports SRA737 licence partner Sierra Oncology to Present on 30 January...more
30/11/2018 Sareum and Sierra Oncology report efficacy for SRA737 Combination...more
13/11/2018 Sareum appoints Michael Owen and Clive Birch as Non-Executive Directors...more
26/10/2018 Sareum Share Placing to raise £850,000 for TYK2/JAK1 programmes...more
01/10/2018 Sareum issues year end results with progress update...more
26/09/2018 Sareum selects SDC-1802 to progress into preclinical development...more
09/08/2018 Sareum notes Sierra Oncology has reported Q2 Results for SRA737...more
31/05/2018 Sareum regains worldwide rights to Aurora+FLT3 inhibitors...more
08/05/2018 Sareum reports Sierra Oncology SRA737 Phase 2 Trial Update...more
24/04/2018 Sareum Notes that Sierra Oncology will Present SRA737 Preclinical Activity at AACR 2018...more
15/03/2018 Sareum notes Sierra Oncology SRA737 abstract accepted for AACR 2018 Meeting...more
27/02/2018 Sareum reports expansion of Sierra Oncology SRA737 Programme...more
26/02/2018 Sareum reports Preclinical Synergy of SRA737 and PARP Inhibitor...more
19/12/2017 Patent Grants in Japan and China for Sareum's TYK2 Inhibitors...more
23/10/2017 Sareum issues final results and highlights for 2017 year end...more
19/06/2017 Sareum Presents at the International Cancer Cluster Showcase 2017...more
31/05/2017 Sareum notes Sierra Oncology announcement of patents for Chk1 inhibitor SRA737...more
10/04/2017 Sareum joins the BioPartner programme...more
